News AVROBIO, Inc.

Equities

AVRO

US05455M1009

Delayed Nasdaq Other stock markets 10:17:06 2024-04-26 am EDT			5-day change	1st Jan Change
1.2 ^USD	+1.27%		0.00%	-11.76%

Mar. 21	North American Morning Briefing : Investors -2-	DJ
Mar. 14	AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure	Mar. 27	AQ
North American Morning Briefing : Investors -2-	Mar. 21	DJ
AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO	Feb. 14	BU
Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic	Jan. 31	PR
AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders	Jan. 30	BU
Transcript : AVROBIO, Inc., Tectonic Therapeutic, Inc. - M&A Call	Jan. 30
AVROBIO and Tectonic Therapeutic Announce Merger	Jan. 30	BU
AVROBIO, Inc. entered into an agreement to acquire Tectonic Therapeutic, Inc.	Jan. 29	CI
North American Morning Briefing : S&P 500 Eyes -2-	Dec. 19	DJ
Mizuho Securities Cuts Avrobio Price Target to $2 From $5, Buy Rating Kept	Dec. 18	MT
North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
North American Morning Briefing : China Angst -2-	23-08-15	DJ
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Wells Fargo Adjusts Price Target on AVROBIO to $2 From $2.50, Maintains Overweight Rating	23-07-13	MT
North American Morning Briefing : Optimism Set to -2-	23-07-13	DJ
Sector Update: Health Care Stocks Slipping Late Wednesday	23-07-12	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	23-07-12	MT
Wedbush Downgrades AVROBIO to Neutral From Outperform on Halted Development of Gene Therapy Programs, Exploring Alternatives; PT is $2	23-07-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AVROBIO, Inc.

Equities

AVRO

US05455M1009

Summary

Filters